The Global Gastrointestinal Therapeutics Market by Type, Dosage Form, Application and Geography (2018-2023) - ResearchAndMarkets.com

September 27, 2018

DUBLIN--(BUSINESS WIRE)--Sep 27, 2018--The “Global Gastrointestinal Therapeutics Market - Segmented by Type, Dosage Form, Application and Geography - Growth, Trends, and Forecast (2018 - 2023)” report has been added to ResearchAndMarkets.com’s offering.

The gastrointestinal therapeutics market is expected to register a growth rate of about 5.8% over the forecast period 2018-2023.

The therapeutic management of gastrointestinal diseases and symptoms is majorly through pharmaceutical interventions, whose market is driven by lifestyle changes leading to GI diseases and increasing R&D investments in biologics and biosimilars.

Asia-Pacific has several emerging countries with increasing privatization which is anticipated to provide lucrative opportunities for global companies in this market, over the forecast period.

Gastrointestinal Therapeutics Market is Primarily Driven by Rapid Lifestyle Changes

Other driving factors include rising surgical treatments and hospitalizations due to GI diseases and increasing R&D investments by biopharmaceutical companies in developing biologics and biosimilars.

Increasing Socio-Economic Burden Associated with GI Diseases Hinders the Growth of Gastrointestinal Therapeutics Market

Other factors such as physiological, behavioral, psychosocial, and socio-environmental risk factors, also restrict the populations from reporting the diseases early which reflects low awareness as well as an economic burden, restricting the growth of the gastrointestinal therapeutics market.

Major Developments in the Market

HiFiBiO Therapeutics collaborated with Takeda, in a multi-target agreement for the discovery of breakthrough antibody therapies to potentially treat variety of gastrointestinal diseases, cancers and other disorders. Pluristem Therapeutics Inc was granted patent by the Japan Patent Office for the treatment of Acute Radiation Syndrome (ARS) and its impact on the gastrointestinal tract.

Companies Profiled

Abbott Allergan PLC Astellas Pharma Inc. AstraZeneca Bayer AG GlaxoSmithKline PLC Janssen Pharmaceuticals Inc. (Johnson & Johnson) Pfizer Inc. Salix Pharmaceuticals Takeda Pharmaceutical Company Limited

Key Topics Covered

1. Introduction

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

6. Market Dynamics

7. Market Segmentation

8. Competitive Landscape

9. Key Players

10. Future of the Market

For more information about this report visit https://www.researchandmarkets.com/research/gwdvhd/the_global?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180927005555/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Gastrointestinal Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/27/2018 09:59 AM/DISC: 09/27/2018 09:59 AM


Update hourly